1. Home
  2. CGC vs NAMSW Comparison

CGC vs NAMSW Comparison

Compare CGC & NAMSW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGC
  • NAMSW
  • Stock Information
  • Founded
  • CGC N/A
  • NAMSW N/A
  • Country
  • CGC Canada
  • NAMSW Netherlands
  • Employees
  • CGC N/A
  • NAMSW 29
  • Industry
  • CGC Pharmaceuticals and Biotechnology
  • NAMSW Biotechnology: Pharmaceutical Preparations
  • Sector
  • CGC Health Care
  • NAMSW Health Care
  • Exchange
  • CGC Nasdaq
  • NAMSW Nasdaq
  • Market Cap
  • CGC N/A
  • NAMSW N/A
  • IPO Year
  • CGC N/A
  • NAMSW N/A
  • Fundamental
  • Price
  • CGC $7.13
  • NAMSW $9.00
  • Analyst Decision
  • CGC Sell
  • NAMSW
  • Analyst Count
  • CGC 2
  • NAMSW 0
  • Target Price
  • CGC $4.30
  • NAMSW N/A
  • AVG Volume (30 Days)
  • CGC 3.4M
  • NAMSW N/A
  • Earning Date
  • CGC 08-07-2024
  • NAMSW N/A
  • Dividend Yield
  • CGC N/A
  • NAMSW N/A
  • EPS Growth
  • CGC N/A
  • NAMSW N/A
  • EPS
  • CGC N/A
  • NAMSW N/A
  • Revenue
  • CGC $218,489,706.00
  • NAMSW N/A
  • Revenue This Year
  • CGC $3.59
  • NAMSW N/A
  • Revenue Next Year
  • CGC $5.90
  • NAMSW N/A
  • P/E Ratio
  • CGC N/A
  • NAMSW N/A
  • Revenue Growth
  • CGC N/A
  • NAMSW N/A
  • 52 Week Low
  • CGC $2.76
  • NAMSW N/A
  • 52 Week High
  • CGC $19.20
  • NAMSW N/A
  • Technical
  • Relative Strength Index (RSI)
  • CGC 51.30
  • NAMSW 47.49
  • Support Level
  • CGC $6.22
  • NAMSW $9.40
  • Resistance Level
  • CGC $8.18
  • NAMSW $10.14
  • Average True Range (ATR)
  • CGC 0.48
  • NAMSW 0.44
  • MACD
  • CGC 0.18
  • NAMSW -0.12
  • Stochastic Oscillator
  • CGC 50.24
  • NAMSW 24.31

About NAMSW NewAmsterdam Pharma Company N.V. Warrant

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: